Detection and therapy of neuroblastoma minimal residual disease using [ 64/67 Cu]Cu-SARTATE in a preclinical model of hepatic metastases

ConclusionsClinical experiences of peptide-receptor radionuclide therapy for metastatic disease have been encouraging. This study demonstrates the potential for a theranostic approach using [64/67Cu]Cu-SARTATE for the detection and treatment of SSTR2-positive neuroblastoma MRD.

http://link.springer.com/10.1186/s13550-021-00763-0

Source: EJNMMI Research - February 25, 2021 Category: Radiology Source Type: research